CCL19 enhances CD8⁺ T-cell responses and accelerates HBV clearance.

"Declarations Conflict of interestThe authors declare that they have no conflicts of interest. Ethics statementAll blood samples from patients were approved by the Institutional Review Board of The Fifth People’s Hospital of Wuxi Ethics Committee (Ethics No. 2020-014-1). All animal experiments were conducted in a BSL-2 laboratory facility in accordance with the Guide for the Care and Use of Laboratory Animals and were reviewed and approved by the Model Animal Research Center, Medical School of Nanjing University, China (Approval ID: LY-01). Conflict of interest The authors declare that they have no conflicts of interest."

"Funding This work was funded by the National Natural Science Foundation of China (81701550), The Top Talent Support Program for young and middle-aged people of Wuxi Health Committee (BJ2020094), the Wuxi Key Medical Talents Program (ZDRC024), and the Open Research Fund Program of the State Key Laboratory of Virology of China (2019IOV005)."